ࡱ>  l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1 Courier New1 Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)                + ) , *   Ј ~~ ؈ ~~#؈ ~~ ؈ ~~8#܈ ~~9#܈ ~~4#܈ ~~3#܈ ~~7#܈ ~~83ffff̙̙3f3fff3f3f33333f33 ARGOS THERAPEUTICS INCc No changesTABLE OF CONTENTS"- Balance SheethJIncome StatementkIncome Statement (1)Qz Cash Flows&XRecently Adopted Accounting Sta&%Recently Adopted Accounting (1)&2 Fair Value of Financial Instr&2 Fair Value of Financial I (1)&2 Fair Value of Financial I (2)&2 Fair Value of Financial I (3)&2 Fair Value of Financial I (4)&4 Property and Equipment and As&6 Notes Payable and Gain on Ear&2014 Stock Incentive Plan and 2&!2014 Stock Incentive Plan a (1)&"3Valuation Assumptions for StockDA 9 WarrantsP9 Warrants (1)Y9 Warrants (2)h12 Net Loss Per Share t12 Net Loss Per Share (1)&Comparison of the Three and Six&Research and Development ExpenspCash Flows (1)[Item 6 Exhibits l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } 0}       ARGOS THERAPEUTICS INC 10-Q 08/20/2018 ARGOS THERAPEUTICS, INC.Delaware 56-2110007' (State or other jurisdiction of (I.R.S. Employer  & incorporation or organization) Identification No.)    4233 Technology Drive~ Durham, North Carolina0((Address of principal executive offices) (Zip Code)$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4|pd:zb3'o=PF0*8X> @ l  y  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } U} 8} } $      ARGOS THERAPEUTICS INC 10-Q 08/20/2018 No changesLarge accelerated filer ?Accelerated filer ? Non-accelerated filer7 /? (Do not check if a smaller reporting company)! Smaller reporting company ?   Emerging growth company ?  $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$,~rB6*=PF0*8X> @  l  '*,  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changes Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } y } $ } :}  '     ARGOS THERAPEUTICS INC 10-Q 08/20/2018TABLE OF CONTENTS%PART I. FINANCIAL INFORMATION Item 1.  Financial Statements~   - %Condensed Consolidated Balance Sheets~     (unaudited)  , $Condensed Consolidated Statements of~    Operations (unaudited),$Condensed Consolidated Statements of~ &Comprehensive Loss (unaudited),$Condensed Consolidated Statements of~ Cash Flows (unaudited)1)Notes to Condensed Consolidated Financial~ Statements (unaudited)Item 2.,$Management?s Discussion and Analysis~ 80of Financial Condition and Results of OperationsItem 3.0(Quantitative and Qualitative Disclosures~ About Market RiskItem 4.Controls and Procedures~ "PART II. OTHER INFORMATIONItem 1.Legal Proceedings~ Item 1A. Risk Factors~ Item 2.0(Unregistered Sales of Securities and Use~  of ProceedsItem 6.Exhibits~ D lwkBoG\"qYh !"#$%& ! Signatures~ !"#$$____________________________1%)Created by Morningstar Document Research.0&(http://documentresearch.morningstar.com/ex=PF0*8X> @2&&%%$$!! l  7s?yI  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTSIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } y<} $ }  } $ } y} $ 7                                 ARGOS THERAPEUTICS INC 10-Q 08/20/2018 Balance Sheet December 31,June 30,       ~  ~       Assets         Current assets        !Cash and cash equivalents~  ~ vAssets held for sale~ $ -Prepaid expenses~ lL~ wOther receivables~ f~ Total current assets~ ~ `#Property and equipment, net~ Υ~ 2_ Other assets~ 2~ 2 Total assets~ ,~ r-%Liabilities and Stockholders? DeficitCurrent liabilitiesAccounts payable~ j>;~ ZAccrued expenses~ #M~ ̜ Notes payable~ /~ /2*Current portion of other convertible notes~ n~ o!Total current liabilities~ RG~ C1)Convertible note payable to related party~ ~ j .&Long-term portion of other convertible~ c~ +R notesD l{og{ w"f ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6  Deferred liabilities  ~ r   ~ S !Warrants!!~ !R; !!! !-!" Commitments"" "-""" "-"#Stockholders? deficit########3$+Preferred stock $0.001 par value; 5,000,000$$ $-$$$ $-$1%)shares authorized as of December 31, 2017:&2and June 30, 2018; 0 shares issued and outstanding1')as of December 31, 2017 and June 30, 20182(*Common stock $0.001 par value; 200,000,000((~ (N\(((~ (n(1))shares authorized as of December 31, 20173*+and June 30, 2018; 5,906,620 and 10,586,6614+,shares issued and outstanding as of December",31, 2017 and June 30, 2018,-$Accumulated other comprehensive loss--~ -bQ---~ - -".Additional paid-in capital..~ .r=V...~ .nX./Accumulated deficit//~ /fz,///~ // /#0Total stockholders? deficit00~ 0e000~ 0q031+Total liabilities and stockholders? deficit1~ 1,11~ 1r123$4____________________________15)Created by Morningstar Document Research.06(http://documentresearch.morningstar.com/2 | r=0fH:w=PF0*8X> @z6655441111   l  )ej  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } $4} $ } y} $ } y}  $ } } $ } y} $ )     ARGOS THERAPEUTICS INC 10-Q 08/20/2018Income Statement#Three Months Ended June 30, ! Six Months Ended June 30,  ~  ~  ~  ~           Revenue ~ @  ~ O  ~    ~ mm                   Operating expenses                 Research and development~ 8~ r  ~  v  ~ A"General and administrative~ ~ zR  ~  q  ~ b0,$Impairment of property and equipment - -  ~  k|   -Restructuring costs~ j -  ~  F   -      Total operating expenses~ 6&~ ؇  ~  z&t   ~ vr     Operating loss~ ~ v{  ~  *  ~ >Other income (expense)     Interest income~ Ɗ~ V7  ~  h  ~ JQInterest expense~  ~ Z  ~  b  ~ 6,$Gain on early extinguishment of debt - -  ~  9   -1)Change in fair value of warrant liability~ )~ !  ~  Ƭ  ~ R; Other expense, net -~    ~  ^  ~ z     #Other income (expense), net~ v~ b  ~  ҕ  ~ F     Net loss~ 6~ t ~  9  ~ DlxlqG[-ar !"#$%&'(                 -!%Net loss per share, basic and diluted!!Q!!!Q!! ! (\/! ! !Gz!"""""""""" " " " " """3#+Weighted average common shares outstanding,##~ #D~###~ # ## # ~ # J,~# # #~ #v,#$basic and diluted%$&____________________________1')Created by Morningstar Document Research.0((http://documentresearch.morningstar.com/4[sg?=PF0*8X> @((''&&!!!!!! !!         l  Vy  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome Statement Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } 0} $ }  } $ }  }  $ } } $ }  } $      ARGOS THERAPEUTICS INC 10-Q 08/20/2018Income Statement#Three Months Ended June 30, ! Six Months Ended June 30,  ~  ~  ~  ~  Net loss ~ 6  ~ t  ~ 9  ~                   (  Other comprehensive gain (loss):                0 (Foreign currency translation gain (loss)  ~ )   ~    ~ =   ~        Total comprehensive loss~ F~ jt ~  Z9  ~ *_$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.xl$(\`=PF0*8X> @         l  GG  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1)!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } :} $ }  } $ }  } $ G                                 ARGOS THERAPEUTICS INC 10-Q 08/20/2018 Cash Flows!Six Months Ended June 30,  ~  ~ , $Cash flows from operating activities         Net loss ~ 9  ~  0 (Adjustments to reconcile net loss to net        ) !cash used in operating activities%Depreciation and amortization~ 6~ R9-%Compensation expense related to stock~ .5~ JVoptions.&Issuance of common shares for research -~ )!and development license agreement,$Gain on early extinguishment of debt~ : -1)Impairment loss on property and equipment~ k| -3+Decrease in fair value of warrant liability~ >S0~ %Loss on disposal of equipment~ ~ *"Interest accrued on long-term debt~ ֦~ FW4,Changes in operating assets and liabilities:.&Prepaid expenses and other receivables~ 4~ bAccounts payable~ jol~ Accrued expenses~ Վ~ O3+Current portion of restructuring obligation~ ^ -Deferred liabilities~ ~ .&Manufacturing research and development~   - obligationDl~r5eqD"zM"h:: ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ?          -!%Net cash used in operating activities!!~ !ZR>!!!~ !:)n!""""""""",#$Cash flows from investing activities########*$"Purchase of property and equipment$$~ $U$$$$ $-$4%,Proceeds from sale of property and equipment%%~ %&Y%%%~ %r9%%&&&&&&&&&0'(Net cash (used in) provided by investing''~ '{}'''~ 'r9%'( activities))))))))),*$Cash flows from financing activities********.+&Net proceeds from sale of common stock++~ +K+++~ +֬+-,%Proceeds from issuance of convertible,,~ ,6n,,, ,-,- note payable!.Payments on notes payable..~ .\...~ .^O.-/%Payments on capital lease obligations//~ //// /-/00(Proceeds from exercise of employee stock00~ 0Ƃ000 0-01purchase plan shares02(Net cash (used in) provided by financing22~ 2222~ 2223 activities/4'Effect of exchange rate changes on cash44~ 4<444~ 4415)Net decrease in cash and cash equivalents55~ 5555~ 5 E5-6%Cash, cash equivalents and restricted66666666 7cash8Beginning of period88~ 8= 888~ 8 89 End of period9~ 9999~ 9v9:::::::::8;0Supplemental disclosure of cash flow information;;;;;;;;<Cash paid for interest<~ <®"<<~ <<4=,Supplemental disclosure of noncash investing======== >and financing activities2?*Issuance of warrants in exchange for early??~ ?P??? ?-?DlrjP*~ae;+C;5@ A B C D E F @extinguishment of debt3A+Purchase of property and equipment includedA~ AAA A$-A0B(in accounts payable and accrued expensesC$D____________________________1E)Created by Morningstar Document Research.0F(http://documentresearch.morningstar.com/x['=PF0*8X> @rFFEEDDAAAA<<<<9999     l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } U5} $ }  } $      ARGOS THERAPEUTICS INC 10-Q 08/20/2018-%Recently Adopted Accounting Standards!Cash and cash equivalents~ 92 *Restricted cash included in current assets  ~ *- 4 ,Total cash, cash equivalents, and restricted ~ rg 0 (cash shown in the Condensed Consolidated Statement of Cash Flows$ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$,{ocW F=PF0*8X> @*   l  a  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } U5} $ }  } $      ARGOS THERAPEUTICS INC 10-Q 08/20/2018-%Recently Adopted Accounting Standards!Cash and cash equivalents~ = 2 *Restricted cash included in current assets  ~ *- 4 ,Total cash, cash equivalents, and restricted ~ g  0 (cash shown in the Condensed Consolidated Statement of Cash Flows$ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$,{ocW F=PF0*8X> @*   l  c  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } %} $      ARGOS THERAPEUTICS INC 10-Q 08/20/2018.&2. Fair Value of Financial Instruments Quoted Prices Significant   Significant  Balance as of    in Active  Other   Unobservable   December 31,    Markets for   Observable  Inputs ~    Identical Assets  Inputs   (Level 3)    (Level 1)   (Level 2) Assets                Money-market funds~  $-   $-  ~ "Total assets at fair value~  $-   $-  ~  Liabilities     Warrants $- $- ~  R;   ~ R; 'Total liabilities at fair value $- $- ~  R;   ~ R; $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/47 znbV(, VRF:=PF0*8X> @"$                l  i  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } %} $      ARGOS THERAPEUTICS INC 10-Q 08/20/2018.&2. Fair Value of Financial Instruments Quoted Prices Significant   Significant  Balance as of    in Active  Other   Unobservable  June 30,    Markets for   Observable  Inputs ~    Identical Assets  Inputs   (Level 3)    (Level 1)   (Level 2) Assets                Money-market funds~ b $-   $-  ~ b"Total assets at fair value~ b $-   $-  ~ b Liabilities     Warrants $- $-   $-   $-'Total liabilities at fair value $- $-   $-   $-$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/43 znbV,0ZVJ>=PF0*8X> @"$                l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } 0.} $ } I} $      ARGOS THERAPEUTICS INC 10-Q 08/20/2018.&2. Fair Value of Financial Instruments'Balance as of December 31, 2017~ R; . &Change in fair value during the period  ~  # Balance as of June 30, 2018  $-   $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$,znbVTH<=PF0*8X> @*   l  X  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } a} $      ARGOS THERAPEUTICS INC 10-Q 08/20/2018.&2. Fair Value of Financial InstrumentsAs of December 31, 2017   Amortized Cost  Gross  Gross   Aggregate   Basis   Unrealized   Unrealized  Fair       Holding  Holding  Value       Gains  Losses Money-market funds ~    $-   $-  ~  ~  $-   $-  ~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|znbVnA]=PF0*8X> @              l  c  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } a} $      ARGOS THERAPEUTICS INC 10-Q 08/20/2018.&2. Fair Value of Financial InstrumentsAs of June 30, 2018   Amortized Cost  Gross  Gross   Aggregate   Basis   Unrealized   Unrealized  Fair       Holding  Holding  Value       Gains  Losses Money-market funds ~ b   $-   $-  ~ b ~ b $-   $-  ~ b$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|znbV rEa=PF0*8X> @              l  I  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } 8} $ }  } $ }  } $                            ARGOS THERAPEUTICS INC 10-Q 08/20/2018:24. Property and Equipment and Assets Held for Sale December 31,June 30,  ~  ~      & Office furniture and equipment ~  '  ~  '  Computer equipment  ~ F_<   ~ A7  Computer software  ~    ~ F߿ Laboratory equipment~ BMq~ BhLeasehold improvements~ *~ *+#Total property and equipment, gross~ q)~ &7/Less: Accumulated depreciation and amortization~ 4~ #Property and equipment, net~ Υ~ 2_$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/83 nbVJ~]~rf>=PF0*8X> @Z      l  #$  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } $4} $ } y} $ } y} $ #                                 ARGOS THERAPEUTICS INC 10-Q 08/20/2018A96. Notes Payable and Gain on Early Extinguishment of Debt December 31,June 30,  ~  ~ 2 *Convertible note payable to Pharmstandard, ~   ~ j  " including accrued interest- %Convertible note payable to Invetech,  ~ ^d   ~ mO " including accrued interest1)Convertible note payable to Saint-Gobain,~ F~ r"including accrued interest2*Note payable to Medinet, including accrued~ .~ 6/interestOther notes payable~ ~ ITotal notes payable~ ~ )0(Less current portion of convertible note~ ~ .&payable to Invetech, including accruedinterest0(Less current portion of convertible note~ ~ b2*payable to Saint-Gobain, including accruedinterest/'Less current portion of note payable to~ bV~ V+#Medinet, including accrued interest3+Less current portion of other notes payable~ '~ .&Long-term portion of notes payable and~ ~ 7!convertible notes payableDs lg[OC1 vP`Eg1W> ! " $ ____________________________1!)Created by Morningstar Document Research.0"(http://documentresearch.morningstar.com/ (=PF0*8X> @Z ""!!      l     dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } 0.} $ }  } $ }  }  $ } y} $ }  } $      ARGOS THERAPEUTICS INC 10-Q 08/20/2018G?2014 Stock Incentive Plan and 2014 Employee Stock Purchase Plan#Three Months Ended June 30, ! Six Months Ended June 30,  ~  ~  ~  ~  Research and development ~ z  ~ ,  ~ }8  ~ 6 " General and administrative  ~ (-   ~ +   ~ Z   ~ 6  Restructuring costs  ~ έ    -   ~ ߡ    -                  .&Total stock-based compensation expense~ V~ W* ~  .5  ~ JV$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|aUI=Y4(=PF0*8X> @         l  2  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } 2} $ }  }  $ } } $                             ARGOS THERAPEUTICS INC 10-Q 08/20/2018G?2014 Stock Incentive Plan and 2014 Employee Stock Purchase Plan Number ofWeighted  Weighted   Shares  Average Exercise  Average       Price   Contractual           Term            (in years)+ #Outstanding as of December 31, 2017  ~ *s    ףp=[@     Granted - $-     Exercised - $-     Cancelled~ n(\]@    'Outstanding as of June 30, 2018~  33333]@   zG@     'Exercisable as of June 30, 2018~  ףp=]@   p= ף@     2*Vested and expected to vest as of June 30,~  ףp= ]@   ףp= @ ~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/: aUI=_[x;~%=PF0*8X> @         l  y@  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1) 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } %} $ }  } $} $ } $}  $ } } $} $ } $} $      ARGOS THERAPEUTICS INC 10-Q 08/20/2018UMValuation Assumptions for Stock Option Plans and Employee Stock Purchase PlanStock Option Plan $ Employee Stock Purchase Plan           ! Six Months Ended June 30, ! Six Months Ended June 30,  ~  ~  ~  ~  Risk-free interest rate   )\(@ %   -    HzG? %   -  Dividend yield  ~  %   -   ~  %   - 'Expected option term (in years)~  -   ?   - Volatility~ Z % -  ~  J  %  -$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.}SG;/Zx=PF0*8X> @Z        l  O  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } m)} $ } I } $ }  }  $ }       ARGOS THERAPEUTICS INC 10-Q 08/20/2018 9. Warrants*"Type of Warrant and ClassificationDate of IssuanceNumber of Shares  Exercise Price  Expiration                              Date(s)                Common stock - Equity   9/29/14   ~ @   ffffff@   9/29/21 Common stock - Equity   3/4/16   ~ N0  ~    3/4/21Common stock - Equity6/29/16~ *  ~    6/29/21 Common stock - Liability8/2/16~  ~    8/02/21Common stock - Equity3/6/17~ "N ~  j  3/06/22$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0 }q<Hznb:=PF0*8X> @Z     l  X  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } <(} $ } } $      ARGOS THERAPEUTICS INC 10-Q 08/20/2018 9. Warrants August 2016   Warrants Exercise price ~   Expiration date   August 2, 2021 ) !Total shares issuable on exercise  ~   $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(T}qB}=PF0*8X> @2   l  g  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } :} $ } } $} $ } $} $                             ARGOS THERAPEUTICS INC 10-Q 08/20/2018 9. WarrantsDecember 31, 2017 June 30, 2018     " Exercise price of warrants ~   ~  . &Closing underlying stock price on date ~    $-   of valuation' Expected stock price volatility  ~  %   -  Expected life (in years)p= ף @ -Risk-free interest rateRQ@ % -Expected dividend yield~  % --%Valuation per common share underlying\(\? $- each warrant80Total liability for warrants on the consolidated~ R;  $- balance sheet0(Decrease in fair value during the period~ f~ R; $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:}qiD.&m=PF0*8X> @r     l  s  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } $4} $ } y} $} $ } }  $ } y} $ } y} $      ARGOS THERAPEUTICS INC 10-Q 08/20/201812. Net Loss Per Share#Three Months Ended June 30, ! Six Months Ended June 30,  ~  ~  ~  ~  Net loss ~ 6  ~ t  ~ 9  ~  3 +Weighted average common shares outstanding,  ~ D~   ~     ~ J,~   ~ v,  basic and diluted                 -%Net loss per share, basic and diluted$(4. 13 )Q  (\/  Gz$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,&|~rf=PF0*8X> @         l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } $} $ }  } $ }  }  $ }  } $ }  } $      ARGOS THERAPEUTICS INC 10-Q 08/20/201812. Net Loss Per Share#Three Months Ended June 30, ! Six Months Ended June 30,  ~  ~  ~  ~ ! Stock options outstanding  ~    ~ C    ~ 2   ~ L  Warrants outstanding  ~ *   ~ *   ~ )   ~ * &  Convertible notes outstanding      ~ fX       ~ fX  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(RT~rf=PF0*8X> @J      l  #  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } 1} $ }  } $ }  }  $ } } $ }  } $} $ }  } $ }  } $ }  } $ }  } $ #!!!!!!!!!! ! ! ! ! !!!!!!!!!!!!!!!!!!!ARGOS THERAPEUTICS INC 10-Q 08/20/2018kcComparison of the Three and Six Months Ended June 30, 2017 with the Three and Six Months Ended JuneThree Months Ended ~    %Six Months Ended~  %   June 30,          June 30,  ~  ~   Change  Change ~  ~   Change  Change   (in thousands) Revenue ~   ~   ~     3333336 % ~   ~ ]  ~ Z    *  Operating expenses                                 Research and development~ P~ R=  ~  N  ffffff7 %~ ~ ~ Nffffff;  %"General and administrative~ )~ '  ~  "   %~ g~ N~ B8  %,$Impairment of property and equipment - -    -   -~  -~ V~ r  %Restructuring costs~ b -  ~    ~ r %~ S -~ ^~ r  %       Total operating expenses~ F~ Rd  ~    3333335 %~ .0~ ~ ֱ33333R  %      Loss from operations~ ҁ~   ~    3333335@ %~ ~ {~ T@  %      Interest income~ &~ R  ~  .  _@ %~ ~ ~ ffffff  %Interest expense~ j~   ~  :  333333H@ %~ ~ N~ J fffffQ@  %,$Gain on early extinguishment of debt - -    -   -~  -~ ~   %1)Change in fair value of warrant liability~ :~ N  ~     *~ R;~ ~ R *  Other expense -~     -  ~  %~ ~ ~  *       Net loss~ z~ ƚ ~  2   8@ %~ V~ y~ vwlR@  %D#l=1%U,T[bl !!!"!$ ____________________________1!)Created by Morningstar Document Research.0"(http://documentresearch.morningstar.com/ (=PF0*8X> @ "" !!                   l  _  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and SixCash Flows (1)Item 6 ExhibitsU } 1} $ } $} $ } $}  $ } $} $ } $} $      ARGOS THERAPEUTICS INC 10-Q 08/20/2018)!Research and Development Expenses#Three Months Ended June 30, ! Six Months Ended June 30,  ~  ~  ~  ~    (in thousands)/ 'Direct research and development expense                  by program: Rocapuldencel-T ~ !  ~   ~ *G  ~ 7 AGS-004~ V~ 2  ~  6  ~ f     -%Total direct research and development~ !~ *  ~  ^H  ~ *8program expense,$Commercial manufacturing development - -  ~  .   -expense1)Indirect research and development expense~ .~ *6  ~  &  ~ [     .&Total research and development expense~ P~ R= ~    ~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/< sg[wER;2&=PF0*8X> @          l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensItem 6 ExhibitsU } 0} $ }  } $ } U} $                          ARGOS THERAPEUTICS INC 10-Q 08/20/2018 Cash Flows!Six Months Ended June 30,  ~  ~    (in thousands)     ' Net cash (used in) provided by:         Operating activities ~   ~ W Investing activities~ ~  Financing activities~ ~ o/'Effect of exchange rate changes on cash~ ~ 0(Net increase (decrease) in cash and cash~ 2V~ & equivalents$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4~r5 =PF0*8X> @Z       l  4  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three and Six!Research and Development ExpensCash Flows (1)U } I } $ 4     ARGOS THERAPEUTICS INC 10-Q 08/20/2018Item 6. ExhibitsExhibitDescription of Exhibit  Number     31.1* , $Certification of principal executive .&officer pursuant to Rules 13a-14(a) or0(15d-14(a) of the Securities Exchange Act/'of 1934, as adopted pursuant to Section-%302 of the Sarbanes-Oxley Act of 2002 31.2*,$Certification of principal financial.&officer pursuant to Rules 13a-14(a) or0(15d-14(a) of the Securities Exchange Act/'of 1934, as adopted pursuant to Section-%302 of the Sarbanes-Oxley Act of 2002 32.1#4,Certifications pursuant to 18 U.S.C. Section0(1350, as adopted pursuant to Section 9061)of The Sarbanes-Oxley Act of 2002, by the0(Registrant?s principal executive officer'and principal financial officer101.INSXBRL Instance DocumentD lxl+ :Z*;w}1 !"#$%&'()*+,-./0123    !101.SCH!/!'XBRL Taxonomy Extension Schema Document!""""#101.CAL#4#,XBRL Taxonomy Extension Calculation Linkbase#$$$Document%%%%&101.DEF&3&+XBRL Taxonomy Extension Definition Linkbase&'''Document(((()101.LAB).)&XBRL Taxonomy Extension Label Linkbase)***Document++++,101.PRE,,,$XBRL Taxonomy Extension Presentation,---Linkbase Document....../0$1____________________________12)Created by Morningstar Document Research.03(http://documentresearch.morningstar.com/,|rB!h< |4(=PF0*8X> @332211--,,**))''&&$$##!!   Root Entry FBook  n  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~